Rocket Pharmaceuticals (NASDAQ: RCKT) Price Target Lowered Amid Gene Therapy Developments

• Jefferies analyst Andrew Tsai has lowered the price target for Rocket Pharmaceuticals (NASDAQ: RCKT) to $2.95, with shares currently trading at $2.48.
• The company is advancing its Danon disease program, outlining an FDA-aligned pivotal study plan for its investigational gene therapy, RP-A501.
• Rocket Pharmaceuticals has secured funding, including $35 million from a new Hercules financing facility, extending its cash runway into the third quarter of 2028.

Rocket Pharmaceuticals is a biotechnology company developing innovative gene therapies for rare diseases. Jefferies analyst Andrew Tsai lowers his price target for the gene therapy stock to $2.95. At the time of publication, shares trade at $2.48, about 19% below that target. A price target is an analyst’s estimate of where a stock may trade, offering an investment outlook for biotechnology stocks.

Rocket’s Danon disease program is a key area of focus for the company's rare disease treatment efforts. The company outlines an FDA-aligned pivotal study plan for RP-A501, its investigational gene therapy, as highlighted by MarketBeat. A pivotal study is designed to provide evidence that may support a request for approval. Rocket says there is no approved treatment that changes the course of Danon disease, underscoring the potential impact of its gene therapy development.

Rocket also discusses longer-term Phase I findings and preliminary Phase II observations, as highlighted by MarketBeat. A transcript highlighted by Seeking Alpha focuses on the RP-A501 pivotal trial and early clinical data, but the provided news item does not include trial results. These details do not establish whether the study plan affects Tsai’s new target for the biotech company.

CEO Gaurav Shah says Rocket’s existing resources and an initial $35 million from a new Hercules financing facility are expected to fund operations into the third quarter of 2028. This funding period, known as a cash runway, could extend into 2029 if Rocket qualifies for additional borrowing. Shares are down $0.13, or 4.98%, at $2.48, reflecting recent market movements for the gene therapy innovator.